Polyclonal Antibody to Lecithin Cholesterol Acyltransferase (LCAT)
phosphatidylcholine-sterol O-acyltransferase; Phospholipid-cholesterol acyltransferase
- Product No.PAJ516Hu01
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- SourcePolyclonal antibody preparation
- HostRabbit
- Potencyn/a
- Ig Type IgG
- PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
- LabelNone
- Immunogen RPJ516Hu01-Recombinant Lecithin Cholesterol Acyltransferase (LCAT)
- Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
- TraitsLiquid
- Concentration500µg/mL
- Organism Species MoreMus musculus (Mouse), Rattus norvegicus (Rat)
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies. - DownloadInstruction Manual
- UOM 20µl100µl 200µl 1ml 10ml
- FOB
US$ 105
For more details, please contact local distributors! US$ 245 US$ 350 US$ 875 US$ 3500
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against LCAT. It has been selected for its ability to recognize LCAT in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.5-2ug/ml
Immunocytochemistry in formalin fixed cells: 5-20ug/ml
Immunohistochemistry in formalin fixed frozen section: 5-20ug/ml
Immunohistochemistry in paraffin section: 5-20ug/ml
Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
- Antibody Labeling Customized Service
- Protein A/G Purification Column
- Staining Solution for Cells and Tissue
- Positive Control for Antibody
- Tissue/Sections Customized Service
- Phosphorylated Antibody Customized Service
- Western Blot (WB) Experiment Service
- Immunohistochemistry (IHC) Experiment Service
- Immunocytochemistry (ICC) Experiment Service
- Flow Cytometry (FCM) Experiment Service
- Immunoprecipitation (IP) Experiment Service
- Immunofluorescence (IF) Experiment Service
- Buffer
- DAB Chromogen Kit
- SABC Kit
- Long-arm Biotin Labeling Kit
- Real Time PCR Experimental Service
Magazine | Citations |
Int J Rheum Dis | Plasma phospholipase, γ‐CEHC and antioxidant capacity in fibromyalgia PubMed: 26585319 |
Inflammation. | Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice withExperimental Sepsis. pubmed:28028754 |
British journal of cancer | A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. pubmed:28664912 |
Journal of Agricultural and Food Chemistry | Lipid-lowering effects of medium-chain triglyceride-enriched coconut oil in combination with licorice extracts in experimental hyperlipidemic mice Pubmed: 30244576 |
Experimental and Therapeutic Medicine | Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D‑LC‑MS/MS Doi: 10.3892/etm.2018.6818 |
British Journal of Cancer | Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. Pubmed: 31388184 |
BIOMEDICINE & PHARMACOTHERAPY | The synergistic mechanism of total saponins and flavonoids in Notoginseng− Safflower pair against myocardial ischemia uncovered by an integrated … Pubmed: 32739736 |
Biomedicine & Pharmacotherapy | Pharmacokinetics/pharmacometabolomics-pharmacodynamics reveals the synergistic mechanism of a multicomponent herbal formula, Baoyuan decoction?¡ |
Cell Metab | Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression Pubmed:35235775 |